Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Usama A. Fahmy
Total Records ( 3 ) for Usama A. Fahmy
  Mohammad Y. Alfaifi , SeragEldin I. Elbehairi , Ali A. Shati , Usama A. Fahmy , Nabil A. Alhakamy and Shadab Md
  Background and Objective: Role of dietary phenolic compounds in the modification of pathophysiological conditions in cancer is immense. Thus, ellagic acid (EA), a natural polyphenolic compound has been recognized for its anticancer activity in different preclinical studies. However, clinical application is limited because of its poor aqueous solubility and thereby, inadequate oral bioavailability. The present work was aimed to formulate micellar delivery, an effective nano-delivery tool for EA, using D-α-tocopheryl polyethylene glycol succinate (TPGS) by film-hydration method. Materials and Methods: Film hydration method was introduced to encapsulate EA within the TPGS micellar structure, which was then characterized and evaluated for in vitro release study. EA-TPGS micelle was further exposed to OVACR3 to determine cancer protecting potential of the formulation. Results: The delivery system (EA-TPGS micelles) consists of spherical shape of 113.2±23 nm with 0.260±0.038 PDI and drug-encapsulation efficiency of 88.67%±3.21. In vitro release profile in the phosphate-buffer saline was found to observe sustained pattern with 67.8% cumulative release within 12 h. Further, a dose dependent cytotoxicity of EA-TPGS micelles was observed on OVACR3 cells with an IC50 value of 12.36 μM. EA-TPGS significantly reduced viable cells via arrest of G1 phase of cell cycle and thereby induce apoptosis probably through inhibiting p15 and p21. Decreased fluorescence unit in ROS determination assay also reflected potential antioxidant activity of the EA-TPGS. Conclusion: These findings strengthened that use of EA-TPGS micelles could overcome the limitations in delivery of hydrophobic chemotherapeutics through oral route.
  Mohammad Y. Alfaifi , Ali A. Shati , Mohammed Ali Alshehri , Serag Eldin I. Elbehairi , Usama A. Fahmy and Ohoud Yahya Alshehri
  Background and Objective: Reports revealed atorvastatin (ATR) exerts significant anti proliferative properties against cancer cell lines. Aim of this study was the potentiation of ATR cytotoxic effects against HepG2 cells by using TPGS as a surfactant and loading on PLGA NPs. Materials and Methods: Nanoprecipitation method was used to trap ATR within PLGA nanoparticles, the method uses vitamin E TPGS as an emulsifier. The nanoparticles’ encapsulation efficiency, size, zeta potential (ZP), surface morphology and in vitro drug release were evaluated. Results: The mean size of the particles was 176.2±14.1 nm, they had a ZP of -15.1±4.4 mV and polydispersity index of 0.32 and after 12 h, approximately 96% of raw ATR had dissolved in comparing with 25% of raw ATR. It was found that ATR-NPs was twice as cytotoxic as the raw ATR. In both instances, for HepG2 cells cycle analysis accumulated at the pre-G1 apoptotic phase in response to ATR and ATR-NPs. Indeed, increase of cells at pre-G1 initiated by ATR 4.45 times the normal level, rising to a 24.05-fold increase for ATR-NPS. The ATR annexin V-FITC apoptosis assay showed significant increase in the amount of annexin V-FITC positive apoptotic cells (both early and late apoptosis) in HepG2 cells treated with ATR-NPs. Conclusion: These findings suggested that this formula is a promising therapy for patients with liver cancer.
  Mohammad Y. Alfaifi , Ali A. Shati , Serag Eldin I. Elbehairi , Usama A. Fahmy , Nabil A. Alhakamy and Shadab Md.
  Background and Objective: Febuxostat (FBX) is a proven prophylactic agent in the management of tumor lysis syndrome in patients with malignant tumors. The clinical application of FBX is hindered due to poor solubility and bioavailability. The purpose of the present study was to develop miceller delivery of FBX using an amphiphilic and non-ionic macromolecule, D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) for the treatment of lung cancer. Materials and Methods: FBX-loaded TPGS micelles (TPGS-FBX-M) were formulated by thin-film hydration method and are characterized for particle size and morphology using dynamic light scattering techniques and transmission electron microscopy. Developed miceller formulation of FBX (TPGS-FBX-M) was further evaluated for entrapment efficiency and in vitro release. Results: Nano-sized spherical miceller deliveries of TPGS-FBX-M displayed a release of 72.7% within 12 h. The formulation was employed to assess cytotoxicity in adenocarcinomic human alveolar basal epithelial cells (A549), where TPGS-FBX-M micelles were found to reduce IC50 values as compared to free FBX which might be due to increased uptake of FBX and effectiveness against A549 cells. An increased cell cycle blockade at the G2/M phase improved apoptotic activity and a significant increase in the expression of caspase 3 for TPGS-FBX-M as compared to free FBX incubation in vitro. Conclusion: This impressive drug delivery platform for lipophilic agents can also be used to deliver other hydrophobic chemotherapeutics to target cancer cells for improves efficacy and safety.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility